GLP-1 advertising is one of the hottest areas in digital marketing right now, and Facebook is aggressively policing these ads. If your GLP-1 ads have been banned, you are not alone, and there is a clear path to reinstatement. The demand for GLP-1 compounds has created a surge in advertising, which has prompted Meta to increase enforcement.
We work with compounding pharmacies that produce GLP-1 compounds, including semaglutide and tirzepatide. Facebook treats GLP-1 related content as pharmaceutical advertising, which triggers the platform's highest level of scrutiny. Getting approved requires a strategic approach that goes beyond standard ad optimization.
Why GLP-1 Ads Get Banned on Facebook
Facebook bans GLP-1 ads for several recurring reasons. The platform categorizes GLP-1 drugs as prescription pharmaceuticals, which means they fall under restricted drug advertising policies. Even if your pharmacy compounds GLP-1s under FDA 503A, Facebook still flags any ad that mentions specific drug names or weight loss outcomes.
Additional triggers include affiliate-style landing pages that redirect to telehealth prescribing services, ads that use before-and-after weight loss imagery, and copy referencing specific clinical studies or medical outcomes. Facebook's reviewers are particularly sensitive to weight loss claims.
The Regulatory Framework You Need
FDA 503A allows licensed pharmacists to compound medications for individual patients based on a prescription. If you are advertising compounded GLP-1s, your ads must stay within what 503A permits: you can advertise compounding services, but not specific drug products as treatments. This distinction is critical for Facebook compliance.
FDA 503B applies to outsourcing facilities that compound GLP-1s at scale. The same advertising restrictions apply, with additional requirements around sterility and quality documentation.
DSHEA 1994 is relevant if any of your GLP-1 products are marketed as dietary supplements. Most GLP-1 compounds are prescription drugs, so DSHEA typically does not apply, but knowing the distinction matters for compliance documentation.
The BAV appeal pathway is essential for GLP-1 advertisers. Facebook requires verified business documentation before allowing ads mentioning pharmaceutical compounds.
Our Approach to Getting GLP-1 Ads Approved
Remove drug-specific language from ad copy. Avoid mentioning semaglutide, tirzepatide, or any branded GLP-1 drug name in headlines and descriptions. Use category-level language like compounded GLP-1 therapies or weight management consultations.
Build a compliant landing page. Your landing page must not make disease treatment claims. Describe your compounding services, explain the FDA 503A framework, and require a consultation before any mention of specific products.
Complete BAV verification. Submit your business license, pharmacy license, and domain ownership proof through the Business Asset Verification process. This step alone resolves many recurring ban issues.
Use Facebook's appeal process strategically. When you appeal, reference your 503A compliance documentation. Explain that you are a licensed compounding pharmacy offering consultation-based services, not a pharmaceutical manufacturer.
Case Study: GLP-1 Account Back Online
A compounding pharmacy client specializing in GLP-1 compounds had their entire ad account banned. Their ads mentioned semaglutide by name and included weight loss claims. We rebuilt the campaign around educational content about GLP-1 therapy consultations, removed all drug names from ad copy, completed BAV verification, and submitted an appeal explaining their 503A compliance. The account was reinstated in 4 days with all new ads approved.
Semaglutide Ads Banned on Facebook
Tirzepatide Ads Banned on Meta
Ready to run these ads? Book a call at calendly.com/custodio-2/30min